ELMDHealthcare · Medical DevicesThe 2 Wall Street analysts covering Electromed, Inc. hold a median 12-month price target of $49 — +79.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 31 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Electromed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (99): The business earns solid, repeatable profits on what it owns.
Accruals (26): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ELMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +79.4% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Aug 2026 | Lake Street | Maintains | Buy | — |
| 13 May 2026 | B. Riley Securities | Maintains | Buy | — |
| 12 Feb 2026 | Freedom Broker | Maintains | Buy | — |
| 19 Nov 2025 | Freedom Broker | Maintains | Buy | — |
| 13 Nov 2025 | Roth Capital | Reiterates | Buy | — |
| 27 Aug 2025 | Lake Street | Assumes | Buy | $36 |
| 27 Aug 2025 | Roth Capital | Maintains | Buy | — |
| 22 July 2025 | Roth Capital | Initiates | Buy | — |
| 20 Feb 2025 | B. Riley Securities | Initiates | Buy | — |
| 11 May 2023 | EF Hutton | Reiterates | Buy | — |
| 16 Feb 2023 | EF Hutton | Maintains | Buy | — |
| 15 Feb 2023 | Lake Street | Maintains | Buy | — |
| 28 Dec 2022 | Lake Street | Assumes | Buy | $20 |
| 6 Sept 2022 | EF Hutton | Initiates | Buy | — |
| 5 Aug 2022 | Lake Street | Initiates | Buy | — |
| 24 Nov 2020 | Northland Capital Markets | Initiates | Outperform | — |
| 18 Oct 2019 | Dougherty & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ELMD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Electromed, Inc. returned +12.1% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 35% of US stocks
Cheaper than 38% of US stocks
Cheaper than 22% of US stocks
Cheaper than 25% of US stocks
Higher than 57% of US stocks
Higher than 76% of US stocks
Higher than 90% of US stocks
Higher than 79% of US stocks
Higher than 78% of US stocks
Higher than 84% of US stocks
Higher than 97% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Electromed, Inc. has a market value of $224.1M and an enterprise value of $205.9M.
Revenue in the twelve months to 30 June 2026: $73.8M. The latest quarter grew 11.6% year on year.
Net income over the same four quarters: $11.3M, a 15.3% net margin.
Diluted earnings per share, trailing twelve months: $1.31.
Free cash flow in the twelve months to 30 June 2026: $8.4M, after $1.3M of capital spending.
Electromed, Inc. spent $3.9M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 20.8×; forward P/E: 44.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Electromed, Inc. employs 195 people — $378K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Electromed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Electromed, Inc. announced that it will report its Q1 fiscal 2027 financial results on November 10, 2026.
Why it matters — ELMD watchers may note the scheduled date for the company’s quarterly financial results.
Electromed, Inc. announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference and the LD Micro 20th Annual Main Event. The company's participation in these investor conferences is part of its ongoing engagement with the investment community.
Why it matters — This announcement signals that ELMD will have opportunities to present and engage with investors at two upcoming industry conferences, which could increase visibility for the company.
Electromed's direct-to-patient model, broad payer coverage, and disciplined sales execution are cited as supporting durable SmartVest growth. The bronchiectasis market is described as substantially underpenetrated, offering a long runway for HFCWO adoption, while hospital revenue, though volatile, remains small and increased for the full year.
Why it matters — ELMD watchers would care because the item highlights durable SmartVest growth drivers and an underpenetrated market, while addressing the volatility of the hospital channel as a limited factor.
Seeking Alpha published the transcript of Electromed, Inc.'s Q4 2026 earnings call, based on the item's headline. The transcript covers the company's fourth-quarter earnings discussion for fiscal 2026.
Why it matters — ELMD watchers can review management's commentary from the Q4 2026 earnings call to understand the company's recent performance and outlook directly from its leadership.
Electromed, Inc. reported quarterly earnings of $0.39 per share, surpassing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share in the same quarter a year ago.
Why it matters — The earnings beat marks an improvement over the prior-year quarter and exceeds analyst expectations, which is relevant to ELMD watchers tracking the company's financial performance.
The 2 Wall Street analysts covering Electromed, Inc. have a median 12-month price target of $49, with estimates ranging from $47 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Electromed, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Electromed, Inc. 91 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Electromed, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +79.4% from the last close, and Ticker Nerd's factor model ranks Electromed, Inc. 91 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Electromed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $47 to $50 over the next 12 months.
Electromed, Inc. returned +12.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Electromed, Inc. is a medical device company focused on airway clearance therapy for patients with compromised pulmonary function.
The most recent item we track (Business Wire, 27 Oct 2026): "Electromed, Inc. to Report Q1 Fiscal 2027 Financial Results on November 10, 2026". Electromed, Inc. announced that it will report its Q1 fiscal 2027 financial results on November 10, 2026.
Electromed, Inc. is a medical device company focused on airway clearance therapy for patients with compromised pulmonary function. The company develops, manufactures, markets, and sells the SmartVest airway clearance system and related products that use high frequency chest wall oscillation (HFCWO) to help mobilize airway secretions. Its portfolio includes home-use therapy systems as well as products designed for acute care settings, serving patients with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Electromed also offers connected therapy solutions that support communication between patients and physicians and help monitor treatment use. Headquartered in New Prague, Minnesota, Electromed plays a specialized role in respiratory care by providing noninvasive airway management tools used by clinicians, patients, and healthcare providers in the United States and selected international markets.
CEO Mr. James L. Cunniff · 195 employees · United States · https://smartvest.com
